Sandoz Enters Canada With First Denosumab Biosimilar
Jubbonti Is Canada’s First and Only Denosumab Biosimilar For Osteoporosis
Sandoz has truly established its position as the frontrunner in the denosumab race after a Canadian approval, but the path to the US market has been hindered by a lawsuit from the originator Amgen.
